<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02201368</url>
  </required_header>
  <id_info>
    <org_study_id>2007/084</org_study_id>
    <secondary_id>2007-005578-29</secondary_id>
    <nct_id>NCT02201368</nct_id>
  </id_info>
  <brief_title>Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation Defects</brief_title>
  <official_title>Study to Evaluate the Effectiveness of Dietary Treatment With Triheptanoin in Patients With Long-chain Fatty Acid Beta-oxidation Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Luz Couce Pico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Ramón Domínguez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinico Universitario de Santiago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if administration Triheptanoin is an effective
      treatment for defects of the long-chain fatty acid beta-oxidation in young adults or adults.
      Period of treatment and follow-up will be 16 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Triheptanoin treatment, in patients with long-chain fatty acid beta-oxidation defects, could
      cause not only a great improvement in their quality of life, also could prevent
      life-threatening signs, reducing symptoms and serious complications of their disease, like
      cardiomyopathy, Reye-like syndrome episodes and rhabdomyolysis. This result would occur by
      the effect of propionyl CoA primer on the Krebs cycle and, at the same time, would produce a
      gluconeogenic effect.

      This treatment opens the door to be used in other diseases such as pyruvate carboxylase
      deficiency, glycogen storage disease and other diseases with energy problems.

      All patients will be followed up until 16 months.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IMP management difficulties
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of metabolic decompensation.</measure>
    <time_frame>up to 16 months</time_frame>
    <description>This is a combined endpoint, including the number and/or severity of episodes of hypoglycemia, rhabdomyolysis, cardiomyopathy and liver failure after starting treatment with trihepatnoin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in the profiles of acylcarnitines with control.</measure>
    <time_frame>6 months and 6 months in each arm treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average values of transaminase and creatin kinase.</measure>
    <time_frame>6 months and 6 months in each arm treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the fatty acid composition of plasma and red blood cells.</measure>
    <time_frame>6 months and 6 months in each arm treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Long-chain Fatty Acid Transport Deficiency</condition>
  <arm_group>
    <arm_group_label>Triheptanoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MCT (Medium-Chain Triglycerides)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triheptanoin (SpezialölÒ 107®)</intervention_name>
    <description>Randomization: Treatment with Triheptanoin for 6 months
Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months
Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months</description>
    <arm_group_label>Triheptanoin</arm_group_label>
    <arm_group_label>MCT (Medium-Chain Triglycerides)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MCT (Medium-Chain Triglycerides)</intervention_name>
    <description>Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months
Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months
Crossover: Treatment with Triheptanoin for 6 months</description>
    <arm_group_label>Triheptanoin</arm_group_label>
    <arm_group_label>MCT (Medium-Chain Triglycerides)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients with any of the following conditions:

          -  Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (LCHAD).

          -  Very long-chain acyl-coenzyme A dehydrogenase deficiency (VLCAD.)

          -  Mitochondrial trifunctional protein (MTP).

          -  Carnitine palmitoyltransferase I deficiency (CPT I).

          -  Carnitine Palmitoyltransferase II (CPT II).

          -  Carnitine-acylcarnitine translocase deficiency (CACT).

        Positive skin biopsy: patients were deemed to commence the dietary treatment with
        Triheptanoin after evaluating the individual response in vitro in cultured fibroblasts.
        This response is based on the measurement of the production of propionyl-CoA, the
        incubation with fatty acids odd-chain, compared with control group fibroblasts.

        The informed consent must be signed by the patient or family, in the case of minors.

        Exclusion Criteria:

          -  No patient/family collaboration or the application of dietary treatment.

          -  No in vitro test response.

          -  Do not meet the inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mª Luz Couce Pico</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico Universitario de Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaume Campistol Plana</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Joan de Déu. Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mercedes Martínez-Pardo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mónica Ruiz Pons</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Ntra. Sra. de Candelaria. Tenerife</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Teresa García Silva</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital 12 de Octubre. Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Sanjurjo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Cruces de Baracaldo - Bilbao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Koldo Aldamiz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Cruces de Baracaldo - Bilbao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inmaculada García Jiménez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Miguel Servet - Zaragoza</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2013</study_first_submitted>
  <study_first_submitted_qc>July 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2014</study_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinico Universitario de Santiago</investigator_affiliation>
    <investigator_full_name>Maria Luz Couce Pico</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Triglycerides; Lipid Metabolism; Fatty Acids.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

